Notice of Intent to Publish NIDDK Funding Opportunity Announcement: Research Using Subjects from the Type 1 Diabetes TrialNet Pathway to Prevention Natural History Study (Living Biobank) (DP3)


Notice Number: NOT-DK-12-018

Key Dates

Release Date: September 7, 2012
Estimated Publication Date of Announcement: October, 2012
First Estimated Application Due Date: February 21, 2013
Earliest Estimated Award Date: October, 2013
Earliest Estimated Start Date: October, 2013

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) intends to reissue a Funding Opportunity Announcement (FOA), https://grants.nih.gov/grants/guide/pa-files/PAR-11-349.html.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. 

The FOA is expected to be published in Fall of 2012 with an expected receipt date February 21, 2013.

This FOA will utilize the DP3 activity code. Details of the planned FOA are provided below.

Research Initiative Details

A new FOA is planned to continue to fund research in type 1 diabetes. It will be similar to PAR-11-349 and will encourage applications for ancillary studies that use subjects enrolled in (or screened for participation in) the Type 1 Diabetes TrialNet clinical trials network.  Studies are expected to generate scientific discoveries on disease mechanisms, disease pathogenic processes, and biomarkers of disease progression or clinical responses.  This FOA is not intended to fund clinical trials with endpoints for clinical efficacy (including but not limited to C-peptide preservation).

APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.

Inquiries

Please direct all inquiries to:

Lisa M. Spain, Ph.D., Director
Immunobiology of Autoimmune Endocrine Diseases Program
Division of Diabetes, Endocrinology, and Metabolism
National Institute of Diabetes Digestive & Kidney Diseases (NIDDK)
Telephone: 301-451-9871
Email: [email protected]